SCHEMBL22798231

SCHEMBL22798231

COc1cc(C(F)(F)F)ccc1OCCNC(=O)c1ccnc(NC(C)=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.52
GPR52 Q9Y2T5 2/20 0.49
KMT2A Q03164 2/20 0.48
MRGPRX4 Q96LA9 1/20 0.46
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTT P42858 2/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
HSP90AA1 P07900 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595159 0.91 SCN9A (0.51) SCN9AGPR52KMT2AMRGPRX4LMNA
SCHEMBL22809634 0.90 GPR52 (0.51) SCN9AGPR52KMT2AMRGPRX4LMNA
SCHEMBL20595228 0.90 SCN9A (0.54) SCN9AGPR52KMT2AMRGPRX4LMNA
SCHEMBL30450528 0.90 SCN9A (0.66) SCN9AGPR52KMT2AMRGPRX4LMNA
SCHEMBL20595189 0.90 SCN9A (0.66) SCN9AGPR52KMT2AMRGPRX4LMNA
SCHEMBL22798334 0.89 SCN9A (0.53) SCN9AGPR52KMT2AMRGPRX4LMNA
SCHEMBL22797811 0.89 GSK3B (0.52) SCN9AGPR52KMT2AMAPTPDE4A
SCHEMBL22798317 0.89 SCN9A (0.61) SCN9AGPR52MRGPRX4
SCHEMBL20595186 0.87 SCN9A (0.52) SCN9AKMT2AMRGPRX4LMNASMN1; SMN2
SCHEMBL22798297 0.82 SCN9A (0.50) SCN9AGPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885GPR52 1477/4885KMT2A 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.